Demographics
| Characteristic . | ALL . | CML . |
|---|---|---|
| Number of patients | 32 | 8 |
| Pretransplant | ||
| Imatinib resistant/intolerant | 7/2 | 4/0 |
| Imatinib sensitive | 23 | 4 |
| Pretransplant disease phase, N | ||
| CR1, CR2 | 31, 1 | — |
| AP, CP, BC remission | — | 1, 6, 1 |
| Median age, y (range) | 42 (11-65) | 51 (18-54) |
| Sex: male/female | 21/11 | 4/4 |
| Donor, N | ||
| Related | 8 | 2 |
| Unrelated | 24 | 6 |
| Stem cell source, N | ||
| Peripheral blood | 26 | 7 |
| Marrow | 4 | 0 |
| Cord blood | 2 | 1 |
| Conditioning, N | ||
| TBI-based | 21 | 6 |
| Non-TBI-based | 11 | 2 |
| Graft-versus-host disease prophylaxis, N | ||
| CNI + methotrexate | 23 | 5 |
| CNI + mycophenolate mofetil | 3 | 1 |
| CNI + prednisone, or sirolimus + CNI | 3 | 1 |
| CNI alone | 3 | 1 |
| Intrathecal methotrexate after HCT, N | ||
| Yes | 17 | 3 |
| No | 14 | 5 |
| Unknown | 1 | 0 |
| Cytomegalovirus, N | ||
| No reactivation | 14 | 3 |
| Ganciclovir/valganciclovir before day 90 | 17 | 5 |
| Unknown | 1 | 0 |
| Characteristic . | ALL . | CML . |
|---|---|---|
| Number of patients | 32 | 8 |
| Pretransplant | ||
| Imatinib resistant/intolerant | 7/2 | 4/0 |
| Imatinib sensitive | 23 | 4 |
| Pretransplant disease phase, N | ||
| CR1, CR2 | 31, 1 | — |
| AP, CP, BC remission | — | 1, 6, 1 |
| Median age, y (range) | 42 (11-65) | 51 (18-54) |
| Sex: male/female | 21/11 | 4/4 |
| Donor, N | ||
| Related | 8 | 2 |
| Unrelated | 24 | 6 |
| Stem cell source, N | ||
| Peripheral blood | 26 | 7 |
| Marrow | 4 | 0 |
| Cord blood | 2 | 1 |
| Conditioning, N | ||
| TBI-based | 21 | 6 |
| Non-TBI-based | 11 | 2 |
| Graft-versus-host disease prophylaxis, N | ||
| CNI + methotrexate | 23 | 5 |
| CNI + mycophenolate mofetil | 3 | 1 |
| CNI + prednisone, or sirolimus + CNI | 3 | 1 |
| CNI alone | 3 | 1 |
| Intrathecal methotrexate after HCT, N | ||
| Yes | 17 | 3 |
| No | 14 | 5 |
| Unknown | 1 | 0 |
| Cytomegalovirus, N | ||
| No reactivation | 14 | 3 |
| Ganciclovir/valganciclovir before day 90 | 17 | 5 |
| Unknown | 1 | 0 |
AP, accelerated phase; BC, blast crisis; CNI, calcineurin inhibitor; CP, chronic phase; CR, complete remission; IR, imatinib resistant; IS, imatinib sensitive; IT, imatinib intolerant; TBI, total body irradiation.
—, not applicable.